Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Next Previous
X
Search
Trial Profile

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emactuzumab (Primary)
  • Indications Giant cell tumour of tendon sheath
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGENT
  • Sponsors SynOx Therapeutics

    • Most Recent Events

    • 16 May 2024 Status changed from not yet recruiting to recruiting.
    • 30 Apr 2024 According to a SynOx Therapeutics media release, the loan facility provides SynOx with flexibility to fund additional clinical work in TGCT to augment TANGENT, activities to support the successful registration and commercialisation of emactuzumab in TGCT, and potentially to explore the use of emactuzumab in other CSF-1 driven and macrophage-mediated diseases.
    • 30 Apr 2024 According to a SynOx Therapeutics media release, company announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) (Hercules). The transaction strengthens the Companys balance sheet as it executes TANGENT, a registrational Phase 3 study of emactuzumab, SynOxs potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of TGCT.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top